Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer

Biochem Cell Biol. 2019 Apr;97(2):158-164. doi: 10.1139/bcb-2018-0039. Epub 2018 Aug 3.

Abstract

Breast cancer is the most frequent malignant disease in women worldwide. It is a heterogeneous and complex genetic disease with different molecular characteristics. MAPT-AS1, a long non-coding RNA (lncRNA) existing at the anti-sense strand of the MAPT (microtubule associated protein tau) promoter region, was believed to regulate MAPT, which was associated with disease state in Parkinson's disease. But the role of MAPT-AS1 in breast cancer has never been reported. In our study we found that MAPT-AS1 is overexpressed in breast cancer but not in triple negative breast cancer (TNBC), and that high expression of MAPT-AS1 was correlated with better patient survival. In addition, the level of MAPT-AS1 was correlated with the expression of MAPT, and MAPT was associated with survival time in breast cancer. Our study suggests that MAPT-AS1 may play a role and be a potential survival predictive biomarker in breast cancer.

Keywords: MAPT-AS1; breast cancer; cancer du sein; long ARN non codant; long non-coding RNA; patient survival; survie des patientes.

MeSH terms

  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / mortality
  • Breast Neoplasms* / pathology
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Neoplasm Proteins / biosynthesis
  • RNA, Long Noncoding / biosynthesis*
  • RNA, Neoplasm / biosynthesis*
  • Survival Rate
  • tau Proteins / biosynthesis

Substances

  • MAPT protein, human
  • Neoplasm Proteins
  • RNA, Long Noncoding
  • RNA, Neoplasm
  • tau Proteins